25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth factor (anti-VEGF) can be used as an adjuvant therapy which can make operation more easy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: JUNYAN ZHANG
• Collaborator: The First People's Hospital of Xuzhou
• Treatments: Ranibizumab; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• Type II diabetes mellitus with Diabetic Retinopathy

• Vitreous hemorrhage/Proliferation of retinal/Tractional detachment of retina

Exclusion Criteria:

• Fasting blood-glucose more than 8mmol/ml

• Subjects who have operation on vitreous before

• Accompany with other ophthalmology diseases except cataract

• History of vitrectomy surgery in the study eye

• Previous subfoveal focal laser photocoagulation in the study eye

• Previous participation in a clinical trial (for either eye)

• Previous subfoveal focal laser photocoagulation in the study eye

• Other diseases cannot afford Vitrectomy